ORIGINAL ARTICLE

Prognostic significance of CDC25B expression in gliomas

H Nakabayashi¹, M Hara² and K Shimizu¹

¹ Department of Neurosurgery, Kochi University, Kochi Medical School, Kochi, Japan
² Department of Neurosurgery, Osaka City University, Medical School, Osaka, Japan

Correspondence to:
Correspondence to:
Dr H Nakabayashi
Department of Neurosurgery, Kochi University, Kochi Medical School, Kohasu, Oko-cho, Nankoku 783-8505, Japan; nakarinh{at}med.kochi-u.ac.jp

Background: CDC25B is a cell-cycle regulatory protein, which is considered to be related to tumorigenesis and progression of tumours.

Aims: To elucidate the role of CDC25B in glioma, the expression of CDC25B and the association of the CDC25B expression with the clinicopathological parameters were investigated.

Methods: Fifty seven gliomas, which included 21 low-grade astrocytomas, 17 anaplastic astrocytomas and 19 glioblastomas, were studied. Protein expressions of CDC25B were evaluated by immunohistochemical methods. Semiquantitative and real-time RT-PCR analyses for the expression of CDC25B mRNA were also carried out. Disease-free survival (DFS) data were analysed by using the Kaplan–Meier method.

Results: High expression of CDC25B was identified in 18 of the 19 glioblastomas, in 10 of the 17 anaplastic astrocytomas, but not in any of the 21 low-grade astrocytomas. The CDC25B mRNA expression increased with the rise in histological grade. Increased CDC25B expression was correlated significantly with a shorter period of DFS, as shown by multivariate analysis.

Conclusions: Patients with an unfavourable clinical outcome are characterised by the increased expression of CDC25B in their glioma samples. Useful clinical information, especially on its relevance as a prognostic indicator, is provided by the evaluation of CDC25B expression in gliomas.

Abbreviations: DFS, disease-free survival; GAPDH, glyceraldehyde-3-phosphate dehydrogenase

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?